Xenon Pharmaceuticals (XENE) Files Mixed Shelf Registration Statement
- Nasdaq, S&P 500 end lower, dragged down by communications services
- Intel (INTC) Stock Plummets as Expensive Investments Expected to Pressure Margins and FCF, Prompting Three Downgrades to Neutral
- Snap (SNAP) Stock Just Crashed 25% Following Earnings, Analyst Reaction Mixed
- Beyond Meat (BYND) Stock Plunges 14% After Slashing Revenue Outlook Amid a Decrease in Retail Orders
- Dollar pares losses as Powell signals bond taper
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Xenon Pharmaceuticals (NASDAQ: XENE) files mixed shelf registration statement of:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ocular Therapeutix (OCUL) Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
- ASLAN Pharmaceuticals (ASLN) Collaborates with Dr Emma Guttman-Yassky on Identification of ASLAN004-Specific Biomarkers
- NeuroMetrix (NURO) Files $50M Mixed Shelf
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings, FDA, Hot Corp. News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!